Beruzatatug pelitecan vs Patritumab Deruxtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline
Beruzatatug pelitecan
Developed by BioNTech under a licence from MediLink Therapeutics (Suzhou) Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06107686 (registry estimate)
No aligned efficacy figure on record for this race.
Patritumab Deruxtecan
Developed by Daiichi Sankyo and partners
NCT05865990 · Phase 2 · completed
The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: August 2029 · NCT07286149 (registry estimate)
Reported efficacy
Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2. (From baseline to the date of first documented progression, death from any cause, or treatment discontinuation from any reason, whichever came first, assessed up to 12 months); Efficacy: Overall survival (OS) rate at 3 months in cohort 3. (From baseline up to 3 months): LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) (met)
Result source: NCT05865990
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Beruzatatug pelitecan | Patritumab Deruxtecan |
|---|---|---|
| PFS, median | —Trial running · NCT07416994 | —Trial running · NCT05338970 |
| OS, median | —Trial running · NCT07416994 | —Trial running · NCT05338970 |
| ORR | —Trial running · NCT07416994 | —Trial running · NCT05338970 |
| Duration of response, median | —Trial running · NCT07416994 | —Trial running · NCT05338970 |
PFS, median
- Beruzatatug pelitecan
- —Trial running · NCT07416994
- Patritumab Deruxtecan
- —Trial running · NCT05338970
OS, median
- Beruzatatug pelitecan
- —Trial running · NCT07416994
- Patritumab Deruxtecan
- —Trial running · NCT05338970
ORR
- Beruzatatug pelitecan
- —Trial running · NCT07416994
- Patritumab Deruxtecan
- —Trial running · NCT05338970
Duration of response, median
- Beruzatatug pelitecan
- —Trial running · NCT07416994
- Patritumab Deruxtecan
- —Trial running · NCT05338970
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Beruzatatug pelitecan: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER3 · full HR+/HER2- Metastatic Breast Cancer pipeline
Beruzatatug pelitecan
Developed by BioNTech under a licence from MediLink Therapeutics (Suzhou) Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06107686 (registry estimate)
No aligned efficacy figure on record for this race.
Patritumab Deruxtecan
Developed by Daiichi Sankyo and partners
NCT02980341 · Phase 1/2 · completed
The study was labeled randomized, but it was open-label and contained only patritumab deruxtecan dose-escalation, dose-finding, and dose-expansion cohorts, with no placebo or active comparator. Although tumor response was assessed using RECIST and results were posted, there was no controlled primary comparison to establish the drug’s effect.
Next expected readout: April 2027 · NCT04965766 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Beruzatatug pelitecan | Patritumab Deruxtecan |
|---|---|---|
| PFS, median | —Trial running · NCT07461454 | 7.2bNCT046996302 other results
|
| OS, median | —Trial running · NCT07461454 | —Trial running · NCT07060807 |
| ORR | —Trial running · NCT07461454 | 35%bNCT046996302 other results
|
| Clinical benefit rate | —Trial running · NCT07461454 | 48.3%bNCT046996302 other results
|
PFS, median
- Beruzatatug pelitecan
- —Trial running · NCT07461454
- Patritumab Deruxtecan
- 7.2bNCT04699630
2 other results
- 2.6 NCT04699630
- 1.4 NCT04699630
OS, median
- Beruzatatug pelitecan
- —Trial running · NCT07461454
- Patritumab Deruxtecan
- —Trial running · NCT07060807
ORR
- Beruzatatug pelitecan
- —Trial running · NCT07461454
- Patritumab Deruxtecan
- 35%bNCT04699630
2 other results
- 5% NCT04699630
- 4.8% NCT04699630
Clinical benefit rate
- Beruzatatug pelitecan
- —Trial running · NCT07461454
- Patritumab Deruxtecan
- 48.3%bNCT04699630
2 other results
- 5% NCT04699630
- 4.8% NCT04699630
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Beruzatatug pelitecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Beruzatatug pelitecan: 0 of 4 rows · Patritumab Deruxtecan: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Patritumab Deruxtecan |
|---|---|
| Dropout rate | n/a: no completion milestone8.0 mg/kga NCT02980341 · Phase 1/2 show 11 more resultsn/a: no completion milestone6.4 mg/kg NCT02980341 · Phase 1/2 —6.4 mg/kg NCT02980341 · Phase 1/2 —6.4 mg/kg NCT02980341 · Phase 1/2 —6.4 mg/kg NCT02980341 · Phase 1/2 n/a: no completion milestone4.8 mg/kg NCT02980341 · Phase 1/2 —4.8 mg/kg NCT02980341 · Phase 1/2 n/a: no completion milestone3.2 mg/kg NCT02980341 · Phase 1/2 n/a: no completion milestone1.6 mg/kg NCT02980341 · Phase 1/2 n/a: no completion milestonePart A NCT04699630 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePart B NCT04699630 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePart Z NCT04699630 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 33.3%8.0 mg/kga NCT02980341 · Phase 1/2 show 11 more results13.3%6.4 mg/kg NCT02980341 · Phase 1/2 —6.4 mg/kg NCT02980341 · Phase 1/2 —6.4 mg/kg NCT02980341 · Phase 1/2 —6.4 mg/kg NCT02980341 · Phase 1/2 6.7%4.8 mg/kg NCT02980341 · Phase 1/2 —4.8 mg/kg NCT02980341 · Phase 1/2 0%3.2 mg/kg NCT02980341 · Phase 1/2 0%1.6 mg/kg NCT02980341 · Phase 1/2 21.7%Part A NCT04699630 · Phase 2 · registry result, not featured evidence 5%Part B NCT04699630 · Phase 2 · registry result, not featured evidence 0%Part Z NCT04699630 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33.3%8.0 mg/kga NCT02980341 · Phase 1/2 show 11 more results60%6.4 mg/kg NCT02980341 · Phase 1/2 38.7%6.4 mg/kg NCT02980341 · Phase 1/2 33.3%6.4 mg/kg NCT02980341 · Phase 1/2 25.8%6.4 mg/kg NCT02980341 · Phase 1/2 20%4.8 mg/kg NCT02980341 · Phase 1/2 30.3%4.8 mg/kg NCT02980341 · Phase 1/2 33.3%3.2 mg/kg NCT02980341 · Phase 1/2 33.3%1.6 mg/kg NCT02980341 · Phase 1/2 20%Part A NCT04699630 · Phase 2 · registry result, not featured evidence 17.5%Part B NCT04699630 · Phase 2 · registry result, not featured evidence 23.8%Part Z NCT04699630 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 11 more results6.4 mg/kg nausea 93.3% white blood cell count decreased 93.3% neutrophil count decreased 86.7% NCT02980341 · Phase 1/2 4.8 mg/kg nausea 73.3% aspartate aminotransferase increased 66.7% neutrophil count decreased 66.7% NCT02980341 · Phase 1/2 nausea 55% fatigue 48.3% diarrhoea 43.3% NCT04699630 · Phase 2 · registry result, not featured evidence nausea 42.5% fatigue 37.5% neutrophil count decreased 32.5% NCT04699630 · Phase 2 · registry result, not featured evidence nausea 52.4% diarrhoea 33.3% neutrophil count decreased 33.3% NCT04699630 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Patritumab Deruxtecan
show 8 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beruzatatug pelitecan's landscape · Patritumab Deruxtecan's landscape